Improving gait adaptability in patients with hereditary spastic paraplegia (Move-HSP): study protocol for a randomized controlled trial

Lotte van de Venis, Bart P C van de Warrenburg, Vivian Weerdesteyn, Bas J H van Lith, Alexander C H Geurts, Jorik Nonnekes, Lotte van de Venis, Bart P C van de Warrenburg, Vivian Weerdesteyn, Bas J H van Lith, Alexander C H Geurts, Jorik Nonnekes

Abstract

Background: People with hereditary spastic paraplegia (HSP) experience difficulties adapting their gait to meet environmental demands, a skill required for safe and independent ambulation. Gait adaptability training is possible on the C-Mill, a treadmill equipped with augmented reality, enabling visual projections to serve as stepping targets or obstacles. It is unknown whether gait adaptability can be trained in people with HSP.

Aim: The aim of Move-HSP is to study the effects of ten 1-h sessions of C-Mill training, compared with usual care, on gait adaptability in people with pure HSP. In addition, this study aims to identify key determinants of C-Mill training efficacy in people with pure HSP.

Method: Move-HSP is a 5-week, two-armed, open-label randomized controlled trial with a cross-over design for the control group. Thirty-six participants with pure HSP will be included. After signing informed consent, participants are randomized (1:1) to intervention or control group. All participants register (near) falls for 15 weeks, followed by the first assessment (week 16), and, thereafter, wear an Activ8 activity monitor for 7 days (week 16). The intervention group receives 10 sessions of C-Mill training (twice per week, 1-h sessions; weeks 17-21), whereas control group continues with usual care (weeks 17-21). Afterwards, both groups are re-assessed (week 22). Subsequently, the intervention group enter follow-up, whereas control group receives 10 sessions of C-Mill training (weeks 23-27), is re-assessed (week 28), and enters follow-up. During follow-up, both groups wear Activ8 activity monitors for 7 days (intervention group: week 23, control group: week 29) and register (near) falls for 15 weeks (intervention group: weeks 23-37, control group: weeks 29-43), before the final assessment (intervention group: week 38, control group: week 44). The primary outcome is the obstacle subtask of the Emory Functional Ambulation Profile. Secondary outcomes consist of clinical tests assessing balance and walking capacity, physical activity, and fall monitoring.

Discussion: Move-HSP will be the first RCT to assess the effects of C-Mill gait adaptability training in people with pure HSP. It will provide proof of concept for the efficacy of gait adaptability training in people with pure HSP.

Trial registration: Clinicaltrials.gov NCT04180098 . Registered on November 27, 2019.

Keywords: C-Mill; Gait adaptability; Hereditary spastic paraplegia; Rehabilitation.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart of the study protocol
Fig. 2
Fig. 2
Overview of the C-Mill training

References

    1. Salinas S, Proukakis C, Crosby A, Warner TT. Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurol. 2008;7(12):1127–1138.
    1. Harding AE. Classification of the hereditary ataxias and paraplegias. Lancet. 1983;1(8334):1151–1155.
    1. McDermott C, White K, Bushby K, Shaw P. Hereditary spastic paraparesis: a review of new developments. J Neurol Neurosurg Psychiatry. 2000;69(2):150–160.
    1. Nonnekes J, van Lith B, van de Warrenburg BP, Weerdesteyn V, Geurts ACH. Pathophysiology, diagnostic work-up and management of balance impairments and falls in patients with hereditary spastic paraplegia. J Rehabil Med. 2017;49(5):369–377.
    1. Harding AE. Hereditary spastic paraplegias. Semin Neurol. 1993;13(4):333–336.
    1. Marsden J, Ramdharry G, Stevenson V, Thompson A. Muscle paresis and passive stiffness: key determinants in limiting function in hereditary and sporadic spastic paraparesis. Gait & posture. 2012;35(2):266–271.
    1. Shribman S, Reid E, Crosby AH, Houlden H, Warner TT. Hereditary spastic paraplegia: from diagnosis to emerging therapeutic approaches. Lancet Neurol. 2019;18(12):1136-46.
    1. Klimpe S, Schule R, Kassubek J, Otto S, Kohl Z, Klebe S, et al. Disease severity affects quality of life of hereditary spastic paraplegia patients. Eur J Neurol. 2012;19(1):168–171.
    1. Bertolucci F, Di Martino S, Orsucci D, Ienco EC, Siciliano G, Rossi B, et al. Robotic gait training improves motor skills and quality of life in hereditary spastic paraplegia. NeuroRehabil. 2015;36(1):93–99.
    1. Nonnekes J, de Niet M, Oude Nijhuis LB, de Bot ST, van de Warrenburg BP, Bloem BR, et al. Mechanisms of postural instability in hereditary spastic paraplegia. J Neurol. 2013;260(9):2387–2395.
    1. van Lith BJH, Kerstens H, van den Bemd LAC, der Sanden M, Weerdesteyn V, Smeets R, et al. Experienced complaints, activity limitations and loss of motor capacities in patients with pure hereditary spastic paraplegia: a web-based survey in the Netherlands. Orphanet J Rare Dis. 2020;15(1):64.
    1. Kerstens H, Satink T, Nijkrake MJ, De Swart BJM, Van Lith BJH, Geurts ACH, et al. Stumbling, struggling, and shame due to spasticity: a qualitative study of adult persons with hereditary spastic paraplegia. Disabil Rehabil. 2020;42(26):3744-51.
    1. Seo HG, Oh BM, Kim K. Robot-assisted gait training in a patient with hereditary spastic paraplegia. PM R. 2015;7(2):210–213.
    1. Heeren A, van Ooijen M, Geurts AC, Day BL, Janssen TW, Beek PJ, et al. Step by step: a proof of concept study of C-Mill gait adaptability training in the chronic phase after stroke. J Rehabil Med. 2013;45(7):616–622.
    1. Fonteyn EM, Heeren A, Engels JJ, Boer JJ, van de Warrenburg BP, Weerdesteyn V. Gait adaptability training improves obstacle avoidance and dynamic stability in patients with cerebellar degeneration. Gait Posture. 2014;40(1):247–251.
    1. Peruzzi A, Zarbo IR, Cereatti A, Della Croce U, Mirelman A. An innovative training program based on virtual reality and treadmill: effects on gait of persons with multiple sclerosis. Disabil Rehabil. 2017;39(15):1557–1563.
    1. Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol. 2010;257(8):1330–1337.
    1. Wissel J, Ward AB, Erztgaard P, Bensmail D, Hecht MJ, Lejeune TM, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009;41(1):13–25.
    1. Schule R, Holland-Letz T, Klimpe S, Kassubek J, Klopstock T, Mall V, et al. The Spastic Paraplegia Rating Scale (SPRS): a reliable and valid measure of disease severity. Neurology. 2006;67(3):430–434.
    1. Counsil MR. Aids to the investigation of the peripheral nervous system. London. Her Majesty's Stationary Office. 1943.
    1. Dyck PJ, Boes CJ, Mulder D, Millikan C, Windebank AJ, Dyck PJ, et al. History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation. J Peripheral Nervous Syst. 2005;10(2):158–173.
    1. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67(2):206–207.
    1. Heyrman L, Molenaers G, Desloovere K, Verheyden G, De Cat J, Monbaliu E, et al. A clinical tool to measure trunk control in children with cerebral palsy: the Trunk Control Measurement Scale. Res Dev Disabil. 2011;32(6):2624–2635.
    1. Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, et al. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) J Neurol. 2013;260(1):228–236.
    1. Wolf SL, Catlin PA, Gage K, Gurucharri K, Robertson R, Stephen K. Establishing the reliability and validity of measurements of walking time using the Emory Functional Ambulation Profile. Phys Ther. 1999;79(12):1122–1133.
    1. Graham JE, Ostir GV, Fisher SR, Ottenbacher KJ. Assessing walking speed in clinical research: a systematic review. J Eval Clin Pract. 2008;14(4):552–562.
    1. van Lith BJH, den Boer J, van de Warrenburg BPC, Weerdesteyn V, Geurts AC. Functional effects of botulinum toxin type A in the hip adductors and subsequent stretching in patients with hereditary spastic paraplegia. J Rehabil Med. 2019;51(6):434–441.
    1. Denton AL, Hough AD, Freeman JA, Marsden JF. Effects of superficial heating and insulation on walking speed in people with hereditary and spontaneous spastic paraparesis: a randomised crossover study. Ann Phys Rehabil Med. 2018;61(2):72–77.
    1. Franchignoni F, Horak F, Godi M, Nardone A, Giordano A. Using psychometric techniques to improve the Balance Evaluation Systems Test: the mini-BESTest. J Rehabil Med. 2010;42(4):323–331.
    1. Leddy AL, Crowner BE, Earhart GM. Functional gait assessment and balance evaluation system test: reliability, validity, sensitivity, and specificity for identifying individuals with Parkinson disease who fall. Phys Ther. 2011;91(1):102–113.
    1. Ross E, Purtill H, Uszynski M, Hayes S, Casey B, Browne C, et al. Cohort study comparing the Berg Balance Scale and the Mini-BESTest in people who have multiple sclerosis and are ambulatory. Phys Ther. 2016;96(9):1448–1455.
    1. Tsang CS, Liao LR, Chung RC, Pang MY. Psychometric properties of the Mini-Balance Evaluation Systems Test (Mini-BESTest) in community-dwelling individuals with chronic stroke. Phys Ther. 2013;93(8):1102–1115.
    1. Valkenet K, Veenhof C. Validity of three accelerometers to investigate lying, sitting, standing and walking. PLoS One. 2019;14(5):e0217545.
    1. de Niet M, de Bot ST, van de Warrenburg BP, Weerdesteyn V, Geurts AC. Functional effects of botulinum toxin type-A treatment and subsequent stretching of spastic calf muscles: a study in patients with hereditary spastic paraplegia. J Rehabil Med. 2015;47(2):147–153.
    1. Powell LE, Myers AM. The Activities-specific Balance Confidence (ABC) Scale. J Gerontol A Biol Sci Med Sci. 1995;50a(1):M28–M34.
    1. Faber I, Martinez ARM, Martins CR, Jr, Maia ML, Souza JP, Lourenco CM, et al. SPG11-related parkinsonism: clinical profile, molecular imaging and l-dopa response. Mov Disord. 2018;33(10):1650–1656.
    1. Zhang Y, Roxburgh R, Huang L, Parsons J, Davies TC. The effect of hydrotherapy treatment on gait characteristics of hereditary spastic paraparesis patients. Gait Posture. 2014;39(4):1074–1079.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj